Hubei Guangji Pharmaceutical Co., Ltd. (Stock Abbreviation: Guangji Pharmaceutical; Stock Code: 000952.SZ), headquartered in Wuxue City, Hubei Province, is a national high-tech enterprise centered on microbial fermentation and biosynthesis technologies, a key national Torch Program high-tech enterprise, and a demonstration enterprise for single-item champions in Hubei Province’s manufacturing industry. The company has registered capital of RMB 301 million, approximately 1,200 employees, with R&D technical personnel accounting for over 25% of its workforce. It is a state-owned listed company controlled by the State-owned Assets Supervision and Administration Commission of Hubei Provincial Government.  

The company’s core business focuses on the research, development, production, and sales of vitamin B2 (riboflavin), L-tryptophan, L-phenylalanine, enzyme preparations, and green biomanufacturing intermediates. Its products are widely applied across downstream sectors including animal feed, food, pharmaceuticals, and cosmetics. Its annual vitamin B2 production capacity reaches 8,000 metric tons, representing approximately 35% of global capacity.  

Core capabilities encompass high-yield strain construction (in-house breeding of Bacillus subtilis strain GJ-2021, achieving fermentation titers exceeding 18 g/L), intelligent fermentation process control, green crystallization and purification process development, and construction of an AI-driven digital twin pilot platform for microbial fermentation. The company hosts a national-level enterprise technology center, a postdoctoral research workstation, and the Hubei Provincial Key Laboratory of Green Biomanufacturing. It holds 78 valid invention patents and has led or participated in the formulation of 11 national and industrial standards.  

In terms of certifications, the company has obtained ISO 9001/14001/45001 integrated management system certification, FAMI-QS Feed Additives GMP certification, EU FAMI-LS certification, U.S. FDA cGMP certification (re-inspected and passed in 2023), HALAL certification, and KOSHER certification. Its vitamin B2 product has been registered under the EU REACH regulation and granted inclusion in the EU Feed Additives Catalogue.  

In 2025, the company achieved revenue of RMB 1.238 billion, with export revenue accounting for 58.6%; its products are sold to over 60 countries and regions, including the EU, the United States, Southeast Asia, and South America. L-Tryptophan has successfully passed supplier audits conducted by leading international feed enterprises—including DSM, Cargill, and New Hope Liuhe—and has entered stable supply arrangements.  

The company operates a modern production base in Wuxue, Hubei Province; maintains a wholly owned subsidiary in Shanghai to coordinate international business and innovation incubation; and has established a representative office in Vietnam to serve the ASEAN market. Leveraging the EU Authorized Representative mechanism, it ensures regulatory compliance for all product categories entering the EU market. Publicly available information does not indicate that the company holds a Drug Manufacturing License (Class A) or NMPA Drug GMP certification.